Celera 'Expediting' Lung Cancer Dx Development Based on Promising Study Results | GenomeWeb

Based on the results of a study presented this week at the American Association for Cancer Research's annual meeting, Celera said it is "expediting" commercialization of its mass spectometry-based lung cancer test.

Specifically, the company has assembled a panel of six protein biomarkers with the ability to detect non-small cell lung cancer in patients with 94 percent sensitivity and 93 percent specificity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.